EICHOR
● Active Not Recruiting
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Condition: Hidradenitis Suppurativa (HS) · Sponsor: Zura Bio Inc
About this study
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (61)
| Medical Dermatology Specialists (Phoenix) | Phoenix, Arizona, United States | — |
| First OC Dermatology Research, Inc. | Irvine, California, United States | — |
| Wallace Medical Group, Inc. | Los Angeles, California, United States | — |
| Northridge Clinical Trials | Northridge, California, United States | — |
| NorCal Clinical Research | Rocklin, California, United States | — |
| Florida Academic Dermatology Center | Coral Gables, Florida, United States | — |
| Skin Care Research, LLC | Hollywood, Florida, United States | — |
| Georgia Skin & Cancer Clinic | Savannah, Georgia, United States | — |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | — |
| The Indiana Clinical Trials Center | Plainfield, Indiana, United States | — |
| Equity Medical LLC (Kentucky) | Bowling Green, Kentucky, United States | — |
| DS Research of Kentucky, LLC | Louisville, Kentucky, United States | — |
+ 49 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.